There can be no guarantees that the Company will determine that any of the potential opportunity under evaluation is worthy of acquisition or investment.
NEW YORK, NY , Jan. 17, 2018 (GLOBE NEWSWIRE) -- Tauriga Sciences (OTC PINK: TAUG) (“Tauriga” or the “Company”), engaged in building its business through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities and equity investments, today announced that the Company is now actively evaluating potential opportunities relating to Blockchain technologies and applications.
On January 4, 2018, the Company announced that its Board of Directors (“BOD”) had voted unanimously in favor of the formation a wholly owned subsidiary focused on acquiring interest(s) in patents and other intellectual property pertaining to Blockchain technology (“Blockchain”). This subsidiary, which was incorporated in Delaware, was named “Tauriga IP Acquisition Corp.” and received financial commitment(s) of up to $300,000 USD from Tauriga’s available cash position.
Tauirga’s CEO Seth M. Shaw expressed, “The Company formed a wholly owned subsidiary earlier this month, in order to be structurally prepared to capitalize on potentially valuable opportunities. Management is now actively evaluating several potential opportunities pertaining to Blockchain and is hopeful to consummate one or more transactions in that sector, should the due diligence process prove satisfactory. The Company believes that it is continuing to make meaningful progress with respect to a number of important corporate initiatives.
There can be no guarantees that the Company will determine that any of the potential opportunity under evaluation is worthy of acquisition or investment, or that the Company will ultimately acquire Blockchain technologies at all.
ABOUT TAURIGA SCIENCES, INC.
Tauriga Sciences, Inc. (OTC PINK: TAUG) is engaged in building business through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities/equity investments. The Company is presently focused on its upcoming contemplated launch of a Cupacu Butter based lip balm product branded under the name: Herman. The Company believes that one of its most important strengths is its access to and relationships with potentially substantial distribution systems and networks. The Company intends to capitalize on distribution opportunities and will continually update shareholders on such developments. Please visit our corporate website at www.tauriga.com
FORWARD-LOOKING STATEMENTS:
This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements.
CONTACT INFORMATION: Tauriga Sciences, Inc. 555 Madison Avenue, 5th Floor New York, NY 10022 Chief Executive Officer Mr. Seth M. Shaw Email: sshaw@tauriga.com cell # (917) 796 9926 www.tauriga.com
